Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

National Cancer Institute

Investor type Government Office

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 64
Average round size
info
The average size of a deal this fund participated in
$2M
Portfolio companies 50
Rounds per year 0.75
Lead investments 12
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 6
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

The leading representative office of defined Corporate Investor is situated in the Bethesda. The fund was located in North America if to be more exact in United States.

The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the National Cancer Institute, startups are often financed by U.S. Department of Defense, National Institutes of Health, National Heart, Lung and Blood Institute. The meaningful sponsors for the fund in investment in the same round are US Department of Energy, National Science Foundation, National Institutes of Health. In the next rounds fund is usually obtained by National Institute of Neurological Disorders and Stroke.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this Corporate Investor is 62 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2019.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of more than 20 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Karmanos Cancer Institute, Wake Forest Baptist Medical Center, Rutgers Universityu2013New Brunswick Among the most popular fund investment industries, there are Health Diagnostics, Neuroscience.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of National Cancer Institute:
Typical Co-investors
National Cancer Institute is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after National Cancer Institute:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Archipelago Advisa Investment Indonesia, Jawa Tengah, Surakarta
BHP Australia, Melbourne, Victoria
Cleantech Open California, Palo Alto, United States
Enfuro Ventures -
Fort Washington Capital Partners Group Cincinnati, Ohio, United States
Fountain Healthcare Partners Dublin, Dublin, Ireland
Global Excel Management Inc. Canada, Quebec, Sherbrooke
GW Holdings LLC Arizona, Paradise Valley, United States
Hyperwise Ventures Israel, Tel Aviv, Tel Aviv
Jennings Capital Inc Alberta, Calgary, Canada
LabCorp Burlington, North Carolina, United States
Marwit California, Newport Beach, United States
Neulogy Ventures Bratislava, Bratislava, Slovakia (Slovak Republic)
PiSA Biopharm Albany, New York, United States
Shell Foundation England, London, United Kingdom
Tuniu China, Jiangsu, Nanjing
Turnaround Management Association Chicago, Illinois, United States
Wenhong Enterprise Management China, Shaanxi, Xian Shi
West Deutsche Landesbank Girozentrale Düsseldorf, Germany, Nordrhein-Westfalen
Yunnan Changtai Touzi China, Kunming, Yunnan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

UAMS Health

Education
Health Care
Non Profit
$1M23 Jun 2022 Little Rock, Arkansas, United States

Immunicom

Biotechnology
$2M14 Jun 2022 San Diego, California, United States

Transcode Therapeutics

Biotechnology
Therapeutics
$1M01 Jun 2022 Boston, Massachusetts, United States

Wake Forest Baptist Medical Center

Education
Health Care
$2M12 Apr 2022 Winston-Salem, North Carolina, United States

GlycoPath

Biotechnology
Clinical Trials
Medical
07 Mar 2022 Charleston, South Carolina, United States

University of Tennessee Health Science Center College of Medicine

Health Care
Higher Education
Medical Device
$3M27 Feb 2022 Memphis, Tennessee, United States

Privo Technologies

Biotechnology
Health Care
Medical
Nanotechnology
Therapeutics
$2M25 Feb 2022 Peabody, Massachusetts, United States

ImmunoPhotonics

Biotechnology
Health Care
Life Science
$2M17 Feb 2022 Columbia, Missouri, United States

Symple Surgical

Health Care
Manufacturing
Medical
Medical Device
Product Research
$399K01 Feb 2022 Flagstaff, Arizona, United States
News
Advanced Chemotherapy Technologies, Inc. Awarded $4 Million NIH Grant to Pursue Treatment for Locally Advanced Non-resectable Pancreatic Cancer

– Advanced Chemotherapy Technologies has been awarded a Phase IIb Small Business Innovation research grant expected to total $4 million over two years from the National Cancer Institute, part of the National Institutes of Health.
– The grant, in combination with prior financing, supports development of the company’s ACT-IOP-003 local drug delivery system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.
– Pancreatic cancer is a devastating disease with 5-year survival rates of only 10%. New treatment modalities are desperately needed and ACT is developing the ACT-IOP-003 system for the targeted delivery of the FDA-approved chemotherapy treatment gemcitabine.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent National Cancer Institute?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: